Thromboembolic disease

The daily dose of sulfinpyrazone is 200-400 mg. The side effects of sulfinpyrazone are comparable with those of probenecid. A potential therapeutic advantage of sulfinpyrazone in patients with coronary heart disease and thromboembolic diseases is its inhibitory effect on platelet aggregation. 

Due to the pivotal role of platelets in thrombus formation, especially in the arterial system, inhibition of platelet function has become a central pharmacological approach. Antiplatelet drugs are given in order to prevent and treat thromboembolic diseases such as coronary heart disease, peripheral and cerebrovascular disease. They have also revolutionized the procedures of invasive coronary interventions as they reduce the risk of restenosis and thrombosis. 

Warning associated with the administration of estrogen include an increased risk of endometrial cancer, gallbladder disease, hypertension, hepatic adenoma (a benign tumor of the liver), cardiovascular disease, increased risk of thromboembolic disease and hypercalcemia in those with breast cancer and bone metastases. 

Zeumer H, Hacke W, Ringelstein EB. Local intraarterial thrombolysis in vertebrobasilar thromboembolic disease. Am J Neuroradiol 1983 4 401 04. 

Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 126 401S-428S. 

Bilateral adrenal hemorrhage or infarction—usually due to anticoagulant therapy, coagulopathy, thromboembolic disease, or meningococcal infection. Causes acute adrenal insufficiency. 

O Heavy smokers (greater than or equal to 15 cigarettes per day) over the age of 35, as well as patients with a history of thromboembolic disease, stroke, coronary artery disease, any estrogen-dependent neoplasm, or undiagnosed abnormal uterine bleeding, should not take estrogen-containing contraceptives. 

HRT should not be prescribed to women with a history of or active thromboembolic disease, breast cancer or estrogen-dependent neoplasm, pregnancy, liver disease, or undiagnosed vaginal bleeding. It also should not be used for the prevention or treatment of cardiovascular disease, cerebrovascular disease, or dementia.11... 

The WHI demonstrated an increased risk in venous thromboembolic disease in the HRT group (0.34%) compared with placebo (0.16%) (HR 2.11,95% Cl 1.58-2.82). This translates into an NNTH of approximately 555 and 18 more cases of venous thromboembolic events for every 10,000 women treated per year with HRT.3 The risk for deep vein thrombosis also was increased in the ERT arm of the WHI, but pulmonary embolism was not increased significantly.21... 

SERMs Hot flushes, signs or symptoms of thromboembolic disease (e.g., pain, redness, or swelling in one extremity chest pain, and shortness of breath). 

Adverse effects include nausea, weight gain, breast tenderness, and breakthrough bleeding. Oral contraceptives have also been associated with an increased incidence of thromboembolic disease, particularly in women who use tobacco products or have other risk factors for thromboembolism. The development of these complications is significantly reduced when low-dose estrogen formulations of oral contraceptives are used.3... 

Women with migraine headaches, history of thromboembolic disease, heart disease, cerebrovascular disease, SLE with vascular disease, and hypertriglyceridemia are good candidates for progestin-only methods (e.g., minip-ills, DMPA, and the levonorgestrel intrauterine system). Women older than 35 years who are smokers or are obese, or who have hypertension or vascular disease, should use progesterone-only methods. 

CVD is a generic denomination mainly integrated by coronary heart disease (CHD) and stroke. Although not considered as a form of CVD in some instances, venous thromboembolic disease (VTED) shares with the other forms of CVD the territorial assignment, the vascular tree, although clear differences exist in the main pathophysiological mechanisms. In most CVD forms, however, thrombus formation plays a crucial role. 

Table 9.1. Risk factors for coronary heart disease and venous thromboembolic disease [adapted from Friedewald (1996) and Rosendaal (1999)]... 

Coronary heart disease Venous thromboembolic disease... 

Cilest contains ethinylestradiol and norgestimate whereas Yasmin contains ethinylestradiol in combination with drospirenone. Both are combined oral contraceptives available as tablets, which have to be taken once daily for 21 days. Both are contraindicated in patients with venous thromboembolic diseases. 

Heparins can be used during pregnancy for the management of thromboembolic disease because they do not cross the placenta. Administration of heparins should be stopped at onset of labour. Low molecular weight heparins are preferred during pregnancy since they pose lower risks of osteoporosis and of heparin-induced thrombocytopenia. 

Thrombocytopenia, heparin-induced For anticoagulation in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease in order to prevent further thromboembolic complications. 

Do not start the patch any earlier than 4 weeks after a second trimester abortion or miscarriage. When the patch is used postpartum or postabortion, the increased risk of thromboembolic disease must be considered. 

Thromboembolic disorders Patients who develop active thrombophlebitis or thromboembolic disease should have the levonorgestrel capsules removed. Also consider removal in women who will be immobilized for a prolonged period due to surgery or other illnesses. 

Current estimates are that oral contraceptive use doubles to triples the overall risk of thromboembolic disease. The increased use in recent years of oral contraceptives with lower estrogen content probably contributes to the decreased risk. However, the risk is... 

Prolonged administration increases the risk of gallbladderdisease, thromboembolic disease, and breast, cervical, vaginal, endometrial, and hepatic carcinoma. 

There Is an Increased risk of cardiovascular disease, endometrial cancer, thromboembolic disease, and worsening dementia,... 

---